Selank Research: What 135 Studies Show (2026) | RetatrutideCompare

Selank — 135 studies indexed on PubMed. Anxiolytic peptide that modulates GABA, serotonin and BDNF in animal models without sedation. Half-life: Several hours (intranasal). FDA status: Not FDA-approved.

PubMed search-result count last fetched 2026-06-18. Records may include reviews, laboratory work, and animal studies; this is not a clinical trial count or a measure of efficacy.

Inspect the PubMed query and results

How many studies have been published on Selank?

There are approximately 135 studies indexed on PubMed that mention Selank (TP-7), based on a search last updated 2026-06-18.

Is Selank FDA-approved?

FDA status: Not FDA-approved.

How does Selank work?

Anxiolytic peptide that modulates GABA, serotonin and BDNF in animal models without sedation.

Anxiolytic peptide that modulates GABA, serotonin and BDNF in animal models without sedation.

Reference facts

Also known as
TP-7
Category
Nootropic & Cognitive
Mechanism of action
Anxiolytic peptide that modulates GABA, serotonin and BDNF in animal models without sedation.
Targets
GABA-A allosteric modulation (indirect), BDNF expression
Indications under research or approved
Approved Russia (generalized anxiety); not US-approved
Regulatory status (reference entry)
Not FDA-approved
Half-life
Several hours (intranasal)
Sequence
TKPRPGP
Sequence notes
Heptapeptide. Synthetic analog of the immunomodulator tuftsin (TKPR) with a stabilizing PGP tail.
Molecular weight (Da)
752
Originator / sponsor
Originally Institute of Molecular Genetics, Moscow
First reported
1991

Primary References

Explore research articles about Selank

This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.